Chonluten

1. Overview

Chonluten (also spelled Honluten, designated T-34) is a synthetic tripeptide with the amino acid sequence Glu-Asp-Gly (EDG) and an approximate molecular weight of 319 g/mol, developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a respiratory system bioregulator [1][7]. It was derived from analysis of bronchial mucosal tissue extracts and is proposed to normalize the function of bronchial epithelial cells through regulation of stress-response, antioxidant, and inflammatory gene pathways [1][3].

Chonluten is often paired with Bronchogen (AEDL) in the Khavinson bioregulator system, as the two peptides target overlapping but complementary pathways in bronchial tissue. While Bronchogen primarily regulates differentiation and mucin genes (NKX2-1, MUC4, MUC5AC), Chonluten focuses on stress-protective pathways including heat shock proteins, antioxidant enzymes, and inflammatory mediators [1][10].

Unlike the AED-based peptides (Cartalax, Bronchogen, Cardiogen, Epithalon), Chonluten has a distinct amino acid composition beginning with glutamic acid and ending with glycine. This structural difference reflects its different tissue derivation (bronchial mucosa rather than organ parenchyma) and distinct gene expression targets.

Limited clinical observational data from Russian studies suggest that oral Chonluten combined with Bronchogen enhances standard therapy in chronic bronchitis and COPD, though no controlled clinical trials have been published.

Molecular Weight

~319 g/mol

Sequence

Glu-Asp-Gly (EDG)

Peptide Type

Synthetic tripeptide bioregulator (Khavinson class)

Mechanism

Stress-response gene regulation (c-Fos, HSP70); antioxidant enzyme modulation (SOD); anti-inflammatory activity (COX-2, TNF-alpha inhibition); bronchial mucosal protection

Routes Studied

Oral (capsules), sublingual, subcutaneous (preclinical)

FDA Status

Not approved; not evaluated by any Western regulatory agency

WADA Status

Not specifically listed; falls under S0 (Non-Approved Substances)

2. Mechanism of Action

Chonluten operates through multiple interconnected protective mechanisms in bronchial epithelial tissue, with emphasis on stress response, antioxidant defense, and anti-inflammatory signaling.

Stress-Response Gene Regulation

The most extensively characterized mechanism of Chonluten involves regulation of cellular stress-response genes. In bronchial epithelial cell cultures, EDG modulates expression of [1][10]:

• c-Fos: An immediate-early gene and component of the AP-1 transcription factor complex involved in cellular stress response, proliferation, and differentiation
• HSP70: Heat shock protein 70, a molecular chaperone that protects proteins from stress-induced denaturation and facilitates cellular recovery from thermal, oxidative, and chemical stress

Antioxidant Enzyme Modulation

Chonluten regulates expression of superoxide dismutase (SOD), a key antioxidant enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide [1]. SOD upregulation is particularly relevant in respiratory tissue, where oxidative stress from inhaled toxins, pollution, and inflammatory processes contributes to epithelial damage and disease progression in conditions such as COPD and asthma.

Anti-Inflammatory Activity

EDG demonstrates direct anti-inflammatory effects through multiple pathways:

• COX-2 inhibition: Chonluten regulates expression of cyclooxygenase-2, the inducible enzyme responsible for prostaglandin synthesis during inflammation [1]
• TNF-alpha suppression: In the THP-1 monocyte/macrophage cell line, Chonluten inhibited tumor necrosis factor (TNF) production by monocytes exposed to bacterial lipopolysaccharide (LPS), a model of acute inflammatory stimulation [2]

These anti-inflammatory effects complement Chonluten's antioxidant properties, addressing two of the primary mechanisms of bronchial epithelial damage in chronic respiratory disease.

Epigenetic Modulation

Studies on aging human cells demonstrated that EDG modulates DNA methylation patterns, suggesting an epigenetic mechanism for its gene-regulatory effects [5]. This is consistent with the broader Khavinson bioregulator theory proposing that short peptides interact with chromatin structure to modulate gene accessibility [3].

DNA and Histone Interaction

Like other Khavinson peptides, EDG is proposed to penetrate cell nuclei and interact with both DNA and histone proteins [3][11]. The peptide binds to histones H1, H2b, H3, and H4 at N-terminal peptide-binding motifs, increasing transcriptional availability of gene promoter zones involved in stress response and mucosal protection [3].

3. Researched Applications

Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Evidence level: Limited clinical (observational), preclinical

Oral administration of Chonluten (EDG) combined with Bronchogen (AEDL) has been reported effective for treatment of bronchopulmonary pathology including COPD and chronic bronchitis with asthmatic component [4][7]. The EDG tripeptide enhanced effectiveness of standard therapy in patients with chronic bronchitis. These clinical observations are from Russian studies and have not been validated through randomized, controlled trials.

The proposed mechanism involves complementary protective effects: Bronchogen maintains epithelial differentiation and mucin production, while Chonluten provides stress protection, antioxidant defense, and anti-inflammatory modulation.

Mucosal Immune Defense

Evidence level: Preclinical (in vitro)

Through its effects on stress-response genes and anti-inflammatory pathways, Chonluten is proposed to support the mucosal immune barrier of the bronchial epithelium [1][4]. The suppression of TNF-alpha production in LPS-stimulated monocytes suggests a role in preventing excessive inflammatory responses that can damage mucosal tissue [2].

Oxidative Stress Protection

Evidence level: Preclinical (in vitro)

Chonluten's regulation of SOD expression and other antioxidant enzyme genes positions it as a potential protective agent against oxidative damage to respiratory epithelium [1]. This application is relevant to exposure to environmental pollutants, cigarette smoke, and oxidative stress associated with respiratory infections.

COVID-19 Related Respiratory Pathology

Evidence level: Theoretical/Review

In a 2020 review, Khavinson and colleagues discussed Chonluten as a potential therapeutic agent for respiratory pathology associated with COVID-19, based on its anti-inflammatory and bronchial epithelium protective properties [4]. No clinical data specific to COVID-19 treatment with Chonluten have been published.

4. Clinical Evidence Summary

5. Dosing in Research

The following table summarizes doses used in published research studies. These are not therapeutic recommendations. Chonluten is not approved for human use in any major regulatory jurisdiction.

Commonly Referenced Protocols

In Russian clinical practice and the bioregulator supplement community, Chonluten is available as oral capsules at 200-400 mcg per dose, taken for courses of 10-30 days and repeated 2-3 times annually. It is frequently combined with Bronchogen for complementary respiratory support. Sublingual administration has also been referenced for potentially improved bioavailability of the intact tripeptide.

6. Safety and Side Effects

Published Safety Data

No adverse effects have been reported in published Chonluten studies. As a tripeptide composed of common L-amino acids (glutamic acid, aspartic acid, glycine), it is expected to be rapidly metabolized by endogenous peptidases into its constituent amino acids. All three amino acids are among the most abundant in normal human metabolism.

In cell culture studies, Chonluten demonstrated protective rather than cytotoxic effects, reducing inflammatory markers and supporting antioxidant defense [1][2].

Critical Safety Gaps

• No formal toxicology studies meeting any regulatory standard
• No dose-escalation or maximum tolerated dose studies
• No pharmacokinetic studies defining absorption, metabolism, or elimination
• No drug interaction studies, particularly with anti-inflammatory medications, bronchodilators, or corticosteroids used in COPD management
• No long-term safety data from controlled human studies
• All safety observations derive from Khavinson's research group

7. Comparison with Related Peptides

Chonluten (EDG) vs. Bronchogen (AEDL)

Both target the bronchial epithelium but through distinct and complementary mechanisms. Bronchogen (AEDL) is a tetrapeptide that primarily activates differentiation genes (NKX2-1, FOXA1, FOXA2) and mucin genes (MUC4, MUC5AC, SFTPA1). Chonluten (EDG) is a tripeptide that regulates stress-response genes (c-Fos, HSP70), antioxidant enzymes (SOD), and inflammatory mediators (COX-2, TNF-alpha). They are commonly used in combination in the Khavinson protocol for respiratory conditions.

Chonluten (EDG) vs. Crystagen (EDP)

Both are tripeptides with the Glu-Asp core but differ in their third amino acid (Gly vs. Pro). This single amino acid difference determines their tissue specificity: Chonluten targets bronchial mucosa while Crystagen targets the immune/thymic system. Both demonstrate anti-inflammatory properties, but Crystagen acts primarily on immune cell populations while Chonluten acts on epithelial stress pathways.

Chonluten vs. Conventional Anti-Inflammatory Agents

Unlike NSAIDs, corticosteroids, or monoclonal antibodies used in respiratory medicine, Chonluten does not act through conventional receptor-mediated pharmacology. Its proposed mechanism involves epigenetic gene regulation rather than direct enzyme inhibition or receptor blockade. No comparative studies with standard-of-care anti-inflammatory agents have been published.

8. Limitations and Transparency

Significant limitations apply to the Chonluten evidence base:

• All published research originates from Khavinson's institute and affiliated laboratories
• Clinical observations in COPD and bronchitis are uncontrolled and not replicated independently
• The specific gene expression effects (c-Fos, HSP70, SOD, COX-2, TNF-alpha) have been characterized primarily in individual in vitro studies
• No randomized, controlled clinical trials have been conducted
• No independent replication by Western research groups
• The molecular mechanism (direct peptide-DNA binding) remains controversial in mainstream molecular biology
• Tripeptide stability and bioavailability following oral administration is a fundamental pharmacokinetic concern

9. Pharmacokinetics

No pharmacokinetic studies have been published for Chonluten (EDG). As a tripeptide of 319 g/mol, it shares the same fundamental pharmacokinetic challenges as Cartalax and other ultrashort Khavinson peptides: extremely rapid proteolytic degradation, uncertain oral bioavailability, and unknown tissue distribution.

Tripeptides are generally degraded within seconds in plasma by serum peptidases. The EDG sequence (Glu-Asp-Gly) contains no structural features that would confer protease resistance -- no D-amino acids, no proline residues in positions that might slow exopeptidase cleavage, and no terminal modifications. Glycine at the C-terminus is readily cleaved by carboxypeptidases [8][12].

PepT1-mediated intestinal transport is theoretically possible for tripeptides, but the contribution of this pathway to intact EDG absorption from oral capsules has not been measured. Sublingual administration, which is referenced in some protocols, could theoretically bypass first-pass hepatic metabolism but still requires the peptide to survive salivary proteases and mucosal transit.

The proposed target tissue (bronchial epithelium) is accessible via systemic circulation through the bronchial arteries. However, no studies have measured intact EDG in bronchial tissue or bronchoalveolar lavage fluid following any route of administration. The entire pharmacokinetic chain -- from oral ingestion to bronchial epithelial cell nuclear entry -- remains uncharacterized.

10. Dose-Response

No dose-response studies have been conducted for Chonluten. The in vitro studies used concentrations spanning 10 to the minus 7 to 10 to the minus 12 M without systematic dose titration [1][10]. The TNF inhibition study in THP-1 monocytes [2] and the stress-response gene modulation studies [1] each used fixed experimental concentrations rather than dose-response designs.

The standard oral protocol (200-400 mcg per day) is generic across Khavinson bioregulators and was not derived from Chonluten-specific dose-finding [7][8]. No studies have compared 200 mcg versus 400 mcg versus higher or lower doses for any clinical or biochemical endpoint. The sublingual protocol (200-400 mcg daily) similarly lacks dose optimization data.

The clinical observational data from COPD and bronchitis patients used Chonluten in combination with Bronchogen, making it impossible to attribute dose-related effects to either peptide individually [4][7]. The contribution of each peptide to the observed clinical improvement is undefined.

11. Comparative Effectiveness

Chonluten (EDG) vs. Bronchogen (AEDL)

These two peptides target the same tissue (bronchial epithelium) through complementary pathways. Bronchogen activates differentiation genes (NKX2-1, MUC4, MUC5AC), while Chonluten modulates stress-response and anti-inflammatory genes (c-Fos, HSP70, SOD, COX-2, TNF-alpha) [1]. No head-to-head comparison exists. The combination is used in Russian clinical practice, but the marginal benefit of adding Chonluten to Bronchogen (or vice versa) has not been quantified in controlled studies.

Chonluten (EDG) vs. Crystagen (EDP)

Both tripeptides share the Glu-Asp core and differ only in the third amino acid (Gly vs. Pro). Both demonstrate anti-inflammatory properties but in different target tissues: Chonluten in bronchial mucosa and Crystagen in the immune/thymic system. This single-amino-acid difference producing a claimed tissue-specificity change is a recurring pattern in the Khavinson system that has not been mechanistically validated.

Chonluten vs. Inhaled Corticosteroids

Inhaled corticosteroids (ICS) are the cornerstone anti-inflammatory therapy for COPD and asthma, with extensive RCT evidence supporting their use. They act through well-characterized receptor-mediated transcriptional regulation of inflammatory genes. Chonluten proposes a fundamentally different mechanism at doses orders of magnitude lower. No comparative data exist, and the clinical evidence gap is vast.

12. Enhanced Safety

No adverse effects have been reported in any Chonluten study [1][2][7]. The tripeptide consists of three of the most abundant amino acids in human metabolism: glutamic acid, aspartic acid, and glycine. All three are non-essential, synthesized endogenously, and consumed daily in gram quantities through dietary protein.

The anti-inflammatory mechanism (COX-2 modulation, TNF-alpha suppression) raises the theoretical question of immunosuppression if these effects extend beyond bronchial tissue. However, the extremely short half-life of the free tripeptide and the proposed tissue-specificity would limit systemic anti-inflammatory effects. The TNF inhibition demonstrated in THP-1 cells [2] was an in vitro observation and may not translate to clinically relevant systemic immunosuppression.

No drug interaction studies have been performed. This is particularly relevant for patients with respiratory conditions who may be taking inhaled corticosteroids, long-acting beta-agonists, phosphodiesterase-4 inhibitors, or systemic immunosuppressants. The potential for additive anti-inflammatory effects (beneficial or harmful) is entirely unknown.

The safety database derives entirely from Khavinson's research network. No independent toxicological assessment, no formal dose-escalation safety studies, and no long-term safety monitoring data exist. The rapid degradation of free tripeptides provides an inherent safety margin against accumulation toxicity.

13. Related Peptides

See also: Bronchogen, Epithalon, Crystagen

14. References

1. [1] Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. DOI PubMed
2. [2] Kuznik BI, Linkova NS, Khavinson VKh. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. International Journal of Molecular Sciences. DOI PubMed
3. [3] Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
4. [4] Khavinson VKh, Linkova NS, Kvetnoy IM. (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed
5. [5] Ashapkin VV, Kutueva LI, Vanyushin BF, Khavinson VKh. (2015). Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Moscow). DOI PubMed
6. [6] Chalisova NI, Linkova NS, Zhekalov AN, Orlova AN, Ryzhak GA, Khavinson VKh. (2006). Tissue-specific effect of synthetic peptide bioregulators in organotypic tissue cultures in young and old rats. Advances in Gerontology (Uspekhi Gerontologii). PubMed
7. [7] Khavinson VKh. (2002). Peptides and ageing. Neuro Endocrinology Letters. PubMed
8. [8] Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
9. [9] Khavinson VKh. (2013). Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Advances in Gerontology (Uspekhi Gerontologii). PubMed
10. [10] Khavinson VKh, Linkova NS, Trofimova SV. (2016). Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine. PubMed
11. [11] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
12. [12] Khavinson VKh, Anisimov VN. (2000). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
13. [13] Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. PubMed
14. [14] Khavinson VKh, Linkova NS, Dyatlova AS, Kuznik BI, Umnov RS. (2021). The use of Thymalin for immunocorrection and molecular aspects of biological activity. Biology Bulletin Reviews. DOI PubMed
15. [15] Khavinson VKh. (2020). Peptide medicines: past, present, future. Klin Med (Mosk).